Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

DNA vaccine induces innate immune response against H pylori

A urease B subunit DNA reduces bacterial colonization in the stomach, even without antigen co-administration, suggesting a greater role for the innate immune responses against H pylori, finds April's Helicobacter.

News image

fiogf49gjkf04

Helicobacter pylori is recognized as a major risk factor for recurrent gastroduodenal inflammatory diseases and gastric adenocarcinoma.

There is a high prevalence of H pylori infection worldwide.

The risks of side-effects from antibiotic therapy, and increasing resistance to antibiotics are the main primers for improved H pylori vaccines.

The antigenic potential of its urease enzyme, a critical virulence factor required for colonization of the gastric mucosa, has been shown in animal and human studies.

An important but controversial issue in H pylori vaccine studies is the type of immune response required to control infection.

The vaccine increased interferon-γ secretion and splenocyte proliferation
Helicobacter

A new approach in H pylori vaccinology is the administration of DNA vaccines, which has included heat-shock protein and catalase DNA vaccines.

Dr Caterina Hatzifoti and colleagues from England administered the H pylori urease subunit B construct or vector alone to mice via the intranasal route.

Spleens and stomachs were examined on day 0 and weeks 3, 6, and 12 after immunization.

The research team assessed proliferation of spleen cells.

The team used the carboxyfluorescein diacetate succinimidyl ester-based flow cytometry assay.

Cytokine secretion from cultured spleen cells was detected by ELISA, after stimulation with the urease subunit B recombinant antigen.

Total RNA was isolated from stomach and spleen tissue.

The research team monitored the expression of β-defensin and cytokine genes by reverse transcription followed by polymerase chain reaction.

Immunized mice were challenged with H pylori and bacterial DNA quantified by TaqMan polymerase chain reaction.

The team found that the urease B subunit DNA vaccine increased interferon-γ secretion and splenocyte proliferation without adverse effects in the spleen.

The research team observed an increase in gastric β-defensin 1.

In addition, the team noted a marked induction in local interleuken-10 to interferon-γ ratio up to 12 weeks post-immunization.

These 2 observations suggest a potential role for local innate immune responses in protection at the site of infection.

The researchers further observed significant bacterial reduction in the stomachs of urease B subunit DNA-immunized mice.

However, intermediate reduction was also noted in the vector group.

The team suggested that increased defensin expression and adjuvant effects of the cytosine preceding guanosine motifs may contribute to this phenomenon.

Dr Hatzifoti's team commented, “In this study, a DNA construct encoding the urease B subunit was assessed for its immune profile and its ability to reduce bacterial colonization in the murine stomach.”

“Our data confirm that cytosine preceding guanosine motifs, even without coadministration with antigen, can reduce extracellular bacterial load.”

“This suggests that local innate immune responses may play a greater role than previously supposed in limiting H pylori colonization in the gastric mucosa.”

Helicobacter 2006: 11(2): 113
06 April 2006

Go to top of page Email this page Email this page to a colleague

 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Esophageal dilatation in clinical practice 
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us